Platelet aggregability in patients with interstitial pneumonias

Area of Science:

• Pulmonary Medicine
• Cardiovascular Medicine
• Hematology

Background:

• Interstitial pneumonias (IPs) are linked to increased cardiovascular event risk.
• Coagulation/fibrinolysis abnormalities are known in idiopathic pulmonary fibrosis (IPF), but platelet function in IPs is understudied.
• This study investigates platelet aggregability in various interstitial pneumonias.

Purpose of the Study:

• To evaluate platelet aggregability in patients with interstitial pneumonias.
• To compare platelet function across different types of interstitial pneumonias and healthy controls.
• To assess the relationship between platelet aggregability, coagulation markers, and disease severity.

Main Methods:

• Observational cohort study of 59 patients with interstitial pneumonias (IPF, other IIPs, CTD-IPs) and 23 controls.
• Measurement of adenosine diphosphate (ADP)- and collagen-induced platelet aggregability using whole blood (WB) and platelet-rich plasma (PRP) techniques.
• Calculation of platelet aggregation threshold index (PATI); assessment of coagulation/fibrinolysis markers (d-dimer, thrombin-antithrombin complex, von Willebrand factor).

Main Results:

• ADP-induced WB-PATI was significantly decreased in CTD-IPs compared to controls, indicating enhanced platelet aggregability.
• No significant difference in platelet aggregability was observed in IPF or other IIPs compared to controls.
• Coagulation and fibrinolysis markers (d-dimer, thrombin-antithrombin complex, von Willebrand factor) were significantly elevated in all IP patient groups versus controls.

Conclusions:

• Serum coagulation and fibrinolysis markers are significantly increased in idiopathic interstitial pneumonias (IIPs) and CTD-IPs.
• Platelet aggregability is only weakly enhanced in CTD-IPs, not in IIPs.
• Elevated coagulation/fibrinolysis markers in IPs may contribute to cardiovascular risk.